Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Prothena and Celgene to Work Together on ALS Therapies

Prothena and Celgene are teaming up to develop treatments for a range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The collaboration will focus on therapies that can target proteins such as tau and TDP-43 that scientists have linked to these disorders. “The programs we have chosen to collaborate…

Top 10 ALS News Stories of 2017

Throughout 2017, ALS News Today brought you daily coverage of amyotrophic lateral sclerosis (ALS)-related advocacy events, clinical studies, and the latest research updates. We have compiled a top 10 list of the most-read ALS news stories of that year, with a brief description of what made them interesting and…